USFDA okays Zydus Cadila schizophrenia drug Brexpiprazole
Ahmedabad: Drugmaker, Zydus Cadila, today announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Brexpiprazole Tablets in the strength of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. (US RLD: Rexulti Tablets).
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD) and for treatment of schizophrenia.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 321 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila ZyCov-D to seek CDSCO nod for two-dose regimen: Report
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
